FBXL17 and cancer: Our studies suggest that compounds that could modify the BTB or DNA-binding domains of BACH1 have the potential to promote the ubiquitination and degradation of BACH1 by FBXL17 or FBXO22, thereby, ameliorating BACH1-mediated cancer metastasis.